New tyrosine kinase inhibitor (TKI) drugs and antibody-drug conjugate (ADC) drugs have been combined in the treatment of HER2+ breast cancer patients 5, 47, but none can replace trastuzumab. The gene discussed is ERBB2; the disease is breast carcinoma.